Stock Analysis

Did Rising International Diagnostics and inVue Dx Adoption Just Shift IDEXX Laboratories' (IDXX) Growth Narrative?

  • In recent months, IDEXX Laboratories reported strong growth in its Companion Animal Group Diagnostics segment, with international recurring revenues rising and a successful rollout of the inVue Dx analyzer leading to an increased full-year installation target.
  • The company's focus on expanding cloud-based software solutions and digital platform acquisitions has further enhanced its global commercial capabilities and reinforced its leadership in veterinary point-of-care testing.
  • We'll examine how the momentum in international diagnostic revenue and instrument adoption impacts IDEXX Laboratories' long-term growth narrative.

Find companies with promising cash flow potential yet trading below their fair value.

Advertisement

IDEXX Laboratories Investment Narrative Recap

To own shares in IDEXX Laboratories, an investor needs to believe in the continued global expansion of advanced veterinary diagnostics, particularly as the company pushes adoption of new platforms like inVue Dx and cloud-based solutions. The recent momentum in international recurring revenues and instrument placements supports the key short-term catalyst, strong growth in the Companion Animal Group Diagnostics segment. Importantly, the latest results do not fully offset the ongoing risk from softening U.S. clinical visit trends, which could limit recurring revenue growth if sustained.

The most relevant recent announcement is IDEXX’s upward revision of full-year revenue and earnings guidance after Q2 2025. This outlook upgrade was driven by robust international demand and the rollout of the inVue Dx analyzer, aligning squarely with the main catalyst of increased diagnostic utilization globally. As these trends progress, they reinforce IDEXX's ability to drive recurring revenues from both consumables and software solutions.

Yet, for investors, it’s equally important to be mindful that softening U.S. clinical visit growth remains a risk, particularly if it continues to pressure...

Read the full narrative on IDEXX Laboratories (it's free!)

IDEXX Laboratories' narrative projects $5.2 billion in revenue and $1.3 billion in earnings by 2028. This requires 8.8% yearly revenue growth and a $314 million earnings increase from the current $985.7 million.

Uncover how IDEXX Laboratories' forecasts yield a $695.09 fair value, a 10% upside to its current price.

Exploring Other Perspectives

IDXX Community Fair Values as at Oct 2025
IDXX Community Fair Values as at Oct 2025

Three perspectives from the Simply Wall St Community estimate IDEXX’s fair value between US$468 and US$695 per share. While international segment gains are supporting recent optimism, you can see how investor opinions differ and explore several alternative viewpoints here.

Explore 3 other fair value estimates on IDEXX Laboratories - why the stock might be worth 26% less than the current price!

Build Your Own IDEXX Laboratories Narrative

Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.

Ready To Venture Into Other Investment Styles?

Our daily scans reveal stocks with breakout potential. Don't miss this chance:

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

New: AI Stock Screener & Alerts

Our new AI Stock Screener scans the market every day to uncover opportunities.

• Dividend Powerhouses (3%+ Yield)
• Undervalued Small Caps with Insider Buying
• High growth Tech and AI Companies

Or build your own from over 50 metrics.

Explore Now for Free

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

About NasdaqGS:IDXX

IDEXX Laboratories

Develops, manufactures, and distributes products for the companion animal veterinary, livestock and poultry, dairy, and water testing industries in the United States and internationally.

Outstanding track record with excellent balance sheet.

Advertisement